How to Buy Cerevel Therapeutics Holdings Stock
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.
Cerevel Therapeutics Holdings stock last closed at $42.47, up 0.95% from the previous day, and has increased 51.3% in one year. It has overperformed other stocks in the Biotechnology industry by 0.73 percentage points. Cerevel Therapeutics Holdings stock is currently +116.79% from its 52-week low of $19.59, and -2.57% from its 52-week high of $43.59.
There are currently 181.58M CERE shares outstanding. The market cap of CERE is $7.71B. In the past 24 hours, 679,080 CERE shares were traded.
How to Buy Cerevel Therapeutics Holdings Stock
Not sure how to invest in Cerevel Therapeutics Holdings stock? Here's how.
- Figure out where to buy Cerevel Therapeutics Holdings stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy Cerevel Therapeutics Holdings stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your payment method and add your info.
- Evaluate Cerevel Therapeutics Holdings stock: The Cerevel Therapeutics Holdings ticker symbol is CERE. Is Cerevel Therapeutics Holdings stock a good investment? Should you buy shares of CERE? How do CERE's underlying business fundamentals look? Do top analysts think Cerevel Therapeutics Holdings is a good buy? Why has CERE's stock price moved recently? (Hint: Our stock research tools can help you evaluate if CERE is a good stock to buy).
- Execute your CERE buy order: Decide if you will purchase CERE shares at the current market price or use a limit order to purchase CERE shares at a specific price.
- Watch your CERE investment: Create a watchlist to track your investment in Cerevel Therapeutics Holdings shares.
Step 1: Figure out where to buy Cerevel Therapeutics Holdings stock
You need a brokerage account in order to access the NASDAQ market and buy CERE stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Utilities, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal details so you are able to buy CERE today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create a new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have finished signing up on the stock trading app, you can securely and quickly fund your account:
Check out the video below for more details depositing money into your new investment account.
Step 4: Evaluate Cerevel Therapeutics Holdings stock
Once you have chosen the best place to buy Cerevel Therapeutics Holdings stock, it's crucial to research their stock before you buy, so you can wrap your head around the risk as well as the upside.
Cerevel Therapeutics Holdings Numbers
Cerevel Therapeutics Holdings Fundamentals
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CERE's stock page.
How is CERE stock valued?
Analysts use many financial metrics, analyses, models, and charts to gauge CERE's true value.
Using relative valuations methods:
- CERE may be overvalued based on its P/B ratio of 11.45x, relative to Biotechnology industry P/B ratio of 5.85x
You can do additional valuation research on CERE's stock here.
CERE Financial Health Overview
Passed Financial Due Diligence Checks:
- CERE has $992.93M in cash and short term investments. This is enough to cover its annual cash burn of $346.11M.
- CERE has cash burn of 346109000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the CERE balance sheet.
- There are more short-term assets than short-term liabilities on the CERE balance sheet.
Failed Financial Due Diligence Checks:
- CERE has a relatively high debt to equity ratio of 0.85.
Is CERE stock a Buy, Hold, or Sell, according to analysts?
Out of 8 Wall Street analysts who give forecasts on CERE, the consensus analyst rating on Cerevel Therapeutics Holdings is a Hold
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent CERE Analyst Recommendations
David Amsellem, a top 25% analyst from Piper Sandler downgrades CERE to a hold rating and raises their CERE price target from $33.00 to $45.00, on Dec 7, 2023.
Charles Duncan, a top 6% analyst from Cantor Fitzgerald downgrades CERE to a hold rating and raises their CERE price target from $38.00 to $45.00, on Dec 7, 2023.
Matthew Harrison, a bottom 12% analyst from Morgan Stanley maintains CERE with a strong buy rating and lowers their CERE price target from $42.00 to $38.00, on Nov 2, 2023.
You can dig deeper into what analysts are projecting on the Cerevel Therapeutics Holdings stock forecast page.
CERE Momentum
Latest Insiders Trades at CERE
In the past 12 months, executives and large shareholders at CERE have bought more shares than they have sold.
N. Anthony Coles, Director of CERE, was the latest CERE insider to sell. They sold $2,116,650.00 worth of CERE stock on Apr 1, 2024.
Learn more about who owns CERE shares here.
Does CERE stock generate passive income?
No, Cerevel Therapeutics Holdings doesn't provide an income stream by paying out dividends.
What others are saying about CERE
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your CERE buy order
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, place a limit order.
Press the Open button and your broker will execute the order.
If you require additional help investing in stocks on eToro, click the helpful video below:
Step 6: Watch your CERE investment
Now that you own some CERE shares, you'll want to stay up-to-date on your new company.
Create a watchlist to get the latest updates about your CERE stock.
CERE Feed
How to Buy Stock in Cerevel Therapeutics Holdings
To summarize, here are the 6 steps to buy stock in Cerevel Therapeutics Holdings:
- Figure out where to buy Cerevel Therapeutics Holdings stock
- Create your brokerage account
- Deposit money your brokerage account
- Evaluate Cerevel Therapeutics Holdings stock
- Execute your CERE buy order
- Watch your CERE investment
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Cerevel Therapeutics Holdings, create your watchlist below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.